10-K: Hyperfine Reports Increased Device Sales in 2024, Focuses on Market Expansion and Cost Streamlining

Hyperfine, Inc. reports a 17% increase in total revenues for 2024, driven by higher device sales and service revenue, while implementing cost-saving measures through organizational restructuring.

Summary

• Hyperfine, Inc. experienced a 17% increase in total revenues, reaching $12.9 million for the year ended December 31, 2024, compared to $11.0 million in 2023.
• The increase in device sales contributed significantly to the revenue growth, with 48 units sold in 2024, a 30% increase from the previous year.
• Service revenues also saw a modest increase of 6.7%, amounting to $2.4 million in 2024.
• The company's net losses amounted to $40.7 million in 2024, slightly lower than the $44.2 million loss in 2023.
• Hyperfine is focusing on expanding its market presence beyond critical care units to include emergency departments, neurology offices, and international markets.
• An organizational restructuring was implemented in January 2025, resulting in a 14% reduction of the global workforce, primarily affecting technical positions, with expected costs of up to $0.4 million.
• The company completed a registered direct offering in February 2025, raising approximately $6.0 million before deducting fees and expenses.
• Hyperfine estimates its total addressable market for Swoop system device placements in the United States alone to be more than $16 billion.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's revenue growth and market expansion, the company is still operating at a loss and faces several risks. The restructuring and capital raise are necessary steps, but also indicate financial pressures.

Positives

• Increased device sales and service revenue indicate growing market acceptance of the Swoop system.
• The company's focus on AI-powered software and continuous innovation is expected to further improve image quality and system performance.
• Expansion into new markets and applications, such as neurology offices and Alzheimer's monitoring, presents significant growth opportunities.
• The company's strong intellectual property portfolio provides a competitive advantage.
• The company has a strong, experienced and lean executive leadership team with deep expertise in health technology.

Negatives

• The company continues to incur net losses, with a $40.7 million loss reported for 2024.
• The company relies on a single contract manufacturer, Benchmark Electronics, Inc., to test, assemble and supply its finished products.
• The company relies on a limited number of suppliers for its products.
• The company has experienced and may continue to experience pricing pressures from contract suppliers or manufacturers on which we rely.

Risks

• The company may need to raise additional capital to fund commercialization plans for its products, including manufacturing, sales and marketing activities, expand its investments in research and development, develop clinical evidence, and commercialize new products and applications.
• The company's success depends upon market acceptance of its products and services, its ability to develop and commercialize existing and new products and services and generate revenues, and its ability to identify new markets for its technology.
• Health technology development is costly and involves continual technological change, which may render the company's current or future products obsolete.
• The company will be dependent upon the success of its sales and customer acquisition and retention strategies.
• If the company is unable to attract, recruit, train, retain, motivate and integrate key personnel and expand its organization, its operations may be disrupted, and it may not achieve its goals.
• The company has limited experience in marketing and selling its products and related services, and if it is unable to successfully commercialize its products and related services, its business and operating results will be adversely affected.
• The company is subject to extensive government regulation, which could restrict the development, marketing, sale and distribution of its products and could cause it to incur significant costs.
• There is no guarantee that the U.S. Food and Drug Administration (the FDA) will grant 510(k) clearance or premarket approval of the company's future products, and failure to obtain necessary clearances or approvals for its future products would adversely affect its ability to grow its business.
• If the company fails to obtain regulatory authorizations in other countries for existing products or products under development, it will not be able to commercialize these products in those countries.
• The company may be subject to enforcement action if it engages in improper or off-label marketing or promotion of its commercial medical device products, including fines, penalties and injunctions.
• Because the company does not require extensive training for users of its current products, although they are limited under the FDAs marketing clearances to use by, and that images generated from the scanner be interpreted by, trained healthcare practitioners, there exists a potential for misuse of these products, misinterpretation of images by untrained professionals or misuse of these products by untrained professionals, which could ultimately harm its reputation and business.
• The company is subject to complex and evolving U.S. and foreign laws and regulations regarding privacy, data protection, and other matters. Many of these laws and regulations are subject to change and uncertain interpretation, and could result in claims or monetary penalties, changes to its business practices, increased cost of operations, or declines in customer growth or engagement, or otherwise harm its business.
• Security breaches, loss of data and other disruptions could compromise sensitive information related to the company's business or prevent it from accessing critical information and expose it to liability, which could adversely affect its business and its reputation.
• If the company is unable to obtain and maintain and enforce sufficient intellectual property protection for its products and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize products similar or identical to ours, and its ability to successfully commercialize its products may be impaired.
• The company currently relies on licenses from third parties, and in the future may rely on additional licenses from other third parties, and if it loses any of these licenses, then it may be subjected to future litigation.
• The company faces the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.
• If the company experiences material weaknesses in its internal control over financial reporting or otherwise fail to maintain an effective system of internal controls in the future, it may not be able to report its financial condition or results of operations accurately or in a timely manner and it may be unable to maintain compliance with applicable stock exchange listing requirements, which may adversely affect investor confidence in it and, as a result, materially and adversely affect its business and the value of its Class A common stock.
• Future sales of substantial amounts of the company's Class A common stock, or the possibility that such sales could occur, could adversely affect the market price of its Class A common stock.
• Because the company is a controlled company within the meaning of the Nasdaq listing rules, its stockholders may not have certain corporate governance protections that are available to stockholders of companies that are not controlled companies.
• The dual class structure of the company's common stock has the effect of concentrating voting power with Jonathan M. Rothberg, Ph.D., the Founder of Legacy Hyperfine and Liminal and a member of its board of directors, which limits an investors ability to influence the outcome of important transactions, including a change in control.

Future Outlook

The company plans to expand its commercial focus beyond critical care units to include emergency departments, neurology offices, and international markets. The company expects that its existing cash and cash equivalents, together with proceeds from the sales of its products and services, will enable it to conduct its planned operations for at least the next 12 months.

Management Comments

• The company is continuously investing in improving its AI-powered image quality and leveraging each imaging-focused software release to further improve the Swoop system performance.

Industry Context

The demand for MR imaging has been increasing due to the aging population and the rising prevalence of neurological, neurodegenerative, and cardiovascular conditions, recent approval of new Alzheimers medications, as well as the trends towards decentralized healthcare in mature, as well as lowand middle-income countries.

Comparison to Industry Standards

• The company's primary competitors include several large companies which currently dominate the medical imaging market, including General Electric, Siemens, Philips, Hologic, Fuji, Toshiba, Canon and Hitachi.
• Neuro42 announced receipt of FDA clearance of its portable MRI system in February 2024 with future plans to commercialize.
• There are several companies currently in the process of developing this technology, including, for example, DeepSpin and Multiwave.

Related Party Transactions

• The Company utilizes and subleases office and lab space in Connecticut, which is being leased from an unrelated landlord by 4Catalyzer Corporation (4C), which is owned by a related party.
• Legacy Hyperfine entered into a Master Services Agreement (the Master Services Agreement) with 4C effective as of July 7, 2021 pursuant to which Hyperfine may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be determined by the parties with respect to any services to be provided.

Stakeholder Impact

• Shareholders may experience dilution due to future equity issuances.
• Employees were affected by the organizational restructuring, resulting in a 14% reduction of the global workforce.
• Customers may benefit from the company's focus on AI-powered software and continuous innovation, which is expected to further improve image quality and system performance.
• The company's expansion into new markets and applications, such as neurology offices and Alzheimer's monitoring, presents significant growth opportunities for the company and its stakeholders.

Next Steps

• The company plans to expand its commercial focus beyond critical care units to include emergency departments, neurology offices, and international markets.
• The company is continuously investing in improving its AI-powered image quality and leveraging each imaging-focused software release to further improve the Swoop system performance.

Key Dates